序号股票简称PE(TTM)PE(静)市净率总市值(元)13南微医学29.2930.224.18167.17亿行业平均 54.3250.504.72116.17亿行业中值38.1137.682.7056.52亿1九安医疗10.9911.120.87185.49亿2新华医疗 15.9814.821.30102.47亿3英科医疗16.0817.331.43254.01亿4山东药玻16.1016.151.85152.30亿5振德医疗 16.4615.511.0559.74亿6奥美医疗16.5616.231.7059.84亿7康德莱17.8617.871.4838.48亿8九强生物 17.9416.682.2088.83亿9维力医疗18.0819.322.2742.38亿10奥泰生物18.1519.131.4757.88亿11鱼跃医疗 19.9219.542.69352.87亿12安图生物20.2719.352.60231.08亿 来源：金融界 南微医学科技股份有限公司的主营业务是微创医疗器械的研发、制造和销售。公司的主要产品是活检 类、止血和闭合类、EMR/ESD类、扩张类、ERCP类、EUS/EBUS类、消融仪、消 ...

8月4日，洛阳钼业今日收盘9.26元，上涨3.12%，滚动市盈率PE（当前股价与前四季度每股收益总和的 比值）达到12.86倍，总市值1981.11亿元。 从行业市盈率排名来看，公司所处的小金属行业市盈率平均65.27倍，行业中值61.48倍，洛阳钼业排名 第5位。 截至2025年一季报，共有212家机构持仓洛阳钼业，其中基金212家，合计持股数42257.90万股，持股市 值35.58亿元。 序号股票简称PE(TTM)PE(静)市净率总市值(元)1洛阳钼业12.8614.642.691981.11亿行业平均 65.2774.134.43230.83亿行业中值61.4863.133.87128.70亿2金钼股份14.4413.832.33412.36亿3锡业股份 18.2520.441.56295.26亿4贵研铂业19.9520.261.61117.39亿5华锡有色20.8521.373.39140.56亿6厦门钨业 21.5120.952.22361.97亿7宝钛股份30.2026.122.14150.55亿8云路股份32.6432.944.60118.91亿9浩通科技 36.0636.782.8142.8 ...

振德医疗用品股份有限公司的主营业务是医疗和健康产品的研发、生产与销售。公司的主要产品是基础 护理、手术感控、压力治疗与固定、造口及现代伤口护理、感控防护。公司曾先后获得包括省级重点企 业研究院、省级工程技术研究中心、省级高新技术企业研究中心、省级企业技术中心、省创新型试点企 业、省级专利示范企业在内的多项技术奖项，并通过国家高新技术企业评审。 8月4日，振德医疗今日收盘22.42元，上涨1.04%，滚动市盈率PE（当前股价与前四季度每股收益总和的 比值）达到16.46倍，创145天以来新低，总市值59.74亿元。 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均54.32倍，行业中值38.11倍，振德医疗排 名第36位。 截至2025年一季报，共有3家机构持仓振德医疗，其中基金3家，合计持股数145.13万股，持股市值0.31 亿元。 来源：金融界 最新一期业绩显示，2025年一季报，公司实现营业收入9.92亿元，同比2.87%；净利润5124.19万元，同 比-30.19%，销售毛利率34.28%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)5振德医疗16.4615.511.0559.74 ...

通策医疗股份有限公司的主营业务是口腔医疗服务的提供、研发。公司的主要产品是医疗服务、产品销 售、建筑工程、综合服务费。 最新一期业绩显示，2025年一季报，公司实现营业收入7.45亿元，同比5.11%；净利润1.84亿元，同比 6.22%，销售毛利率44.21%。 8月4日，通策医疗今日收盘45.33元，下跌1.71%，滚动市盈率PE（当前股价与前四季度每股收益总和的 比值）达到39.59倍，总市值202.76亿元。 从行业市盈率排名来看，公司所处的医疗服务行业市盈率平均47.79倍，行业中值59.03倍，通策医疗排 名第24位。 股东方面，截至2025年5月28日，通策医疗股东户数83145户，较上次减少1346户，户均持股市值35.28 万元，户均持股数量2.76万股。 序号股票简称PE(TTM)PE(静)市净率总市值(元)8通策医疗39.5940.444.82202.76亿行业平均 47.7959.864.17195.49亿行业中值59.0364.343.1867.01亿1药明康德19.1627.924.402638.13亿2康龙化成 28.3729.563.77530.08亿3爱尔眼科32.4133. ...

Group 1 - The core viewpoint of the news is that Jiukang Bio's stock performance shows a significant decline in its earnings compared to the industry average, indicating potential investment concerns [1] - Jiukang Bio's closing price on August 4 was 15.15 yuan, with a PE ratio of 17.94, marking a new low in 72 days and a total market capitalization of 8.883 billion yuan [1] - The company ranks 39th in the medical device industry, which has an average PE ratio of 54.32 and a median of 38.11 [1] Group 2 - In terms of capital flow, Jiukang Bio experienced a net inflow of 16.9344 million yuan on August 4, but overall, there was a net outflow of 3.0466 million yuan over the past five days [1] - The main business of Jiukang Bio includes research, production, and sales of biochemical diagnostics, blood coagulation testing, blood type testing, and tumor pathology diagnostics [1] - The latest financial report for Q1 2025 shows Jiukang Bio achieved revenue of 320 million yuan, a year-on-year decrease of 18.81%, and a net profit of 83.2575 million yuan, down 30.99%, with a gross margin of 80.84% [1]

8月4日，乐普医疗今日收盘16.15元，上涨3.00%，滚动市盈率PE（当前股价与前四季度每股收益总和的 比值）达到211.49倍，创279天以来新低，总市值303.72亿元。 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均54.32倍，行业中值38.11倍，乐普医疗排 名第113位。 乐普(北京)医疗器械股份有限公司的主营业务是医疗器械、药品、医疗服务及健康管理。公司的主要产 品是医疗器械、药品、医疗服务及健康管理。 最新一期业绩显示，2025年一季报，公司实现营业收入17.36亿元，同比-9.67%；净利润3.79亿元，同 比-21.44%，销售毛利率64.03%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13乐普医疗211.49122.991.97303.72亿行业平均 54.3250.504.72116.17亿行业中值38.1137.682.7056.52亿1九安医疗10.9911.120.87185.49亿2新华医疗 15.9814.821.30102.47亿3英科医疗16.0817.331.43254.01亿4山东药玻16.1016.151.85152.30亿5振德医疗 16 ...

Group 1 - The core viewpoint of the articles highlights the performance and valuation of MacAudie, with a closing price of 16.73 yuan and a PE ratio of 52.61, significantly higher than the industry average of 36.62 [1][2] - MacAudie's total market capitalization is reported at 8.656 billion yuan, ranking 101st in the electric grid equipment industry based on PE ratio [1][2] - The company experienced a net outflow of 159,100 yuan in principal funds on August 4, with a total outflow of 33.1437 million yuan over the past five days [1] Group 2 - MacAudie's main business includes the production and sales of epoxy insulation components, optical microscopes, molds, medical testing products, and energy internet technology research and operations [1] - The latest quarterly report for Q1 2025 shows that the company achieved an operating income of 316 million yuan, a year-on-year increase of 5.91%, and a net profit of 34.8816 million yuan, up 9.70%, with a gross profit margin of 41.77% [1]

最新一期业绩显示，2025年一季报，公司实现营业收入7.96亿元，同比-16.49%；净利润2565.19万元， 同比-9.35%，销售毛利率27.96%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13新里程65.8664.343.6673.84亿行业平均 47.7959.864.17195.49亿行业中值59.0364.343.1867.01亿1药明康德19.1627.924.402638.13亿2康龙化成 28.3729.563.77530.08亿3爱尔眼科32.4133.785.501201.11亿4诺禾致源33.6134.732.7068.34亿5华康洁净 33.9248.871.8932.65亿6普蕊斯35.9930.812.7832.79亿7诺思格37.5038.312.8853.72亿8通策医疗 39.5940.444.82202.76亿9凯莱英39.9541.832.31396.94亿10华厦眼科40.6340.042.91171.61亿11万邦医药 48.2338.172.1832.65亿12阳光诺和55.5242.017.2374.52亿 来源：金融界 8月4日，新里程今日收 ...

Core Viewpoint - On August 4, Aoyang Health's stock closed at 4.25 yuan, up 3.41%, with a rolling PE ratio of 114.91, marking a new low in 35 days, and a total market capitalization of 3.254 billion yuan [1] Company Summary - Aoyang Health's main business includes medical services, pharmaceutical distribution, and biotechnology, with key products being medical services and pharmaceutical logistics [1] - The company has received several honors, including third place in the 7th National Hospital Quality Circle Competition and recognition as a demonstration hospital for improving medical services [1] - Aoyang Hospital has signed a contract with the China Trauma Rescue Alliance to enhance its trauma rescue capabilities, significantly reducing mortality and disability rates among severely injured patients [1] - The company ranked 32nd in the non-public hospital top 100 list published by the Alipay Hospital Management Research Center and is second among county-level non-public hospitals nationwide [1] Industry Summary - The average PE ratio for the medical services industry is 47.79, with a median of 59.03, placing Aoyang Health at 39th in the industry ranking [2] - The latest quarterly report for Q1 2025 shows Aoyang Health achieved revenue of 452 million yuan, a year-on-year decrease of 22.27%, and a net profit of 18.4992 million yuan, down 39.82%, with a gross profit margin of 15.09% [2] - Comparatively, the industry average PE (TTM) is 47.79, while Aoyang Health's PE (TTM) stands at 114.91, indicating a significant premium over the industry average [2]

Group 1 - The core viewpoint of the article highlights the performance and valuation of Hongye Futures, which has a current stock price of 12.09 yuan, a PE ratio of 275.06, and a total market capitalization of 12.184 billion yuan [1][2] - Hongye Futures operates in the diversified financial industry, which has an average PE ratio of 70.96 and a median of 29.30, placing Hongye Futures at the 20th position in the industry ranking [1][2] - As of January 10, 2025, Hongye Futures has 40,409 shareholders, a decrease of 517 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares [1] Group 2 - The main business activities of Hongye Futures include commodity futures brokerage, financial futures brokerage, futures investment consulting, asset management, and fund sales [1] - The latest financial results for the first quarter of 2025 show that the company achieved an operating income of 643 million yuan, a year-on-year increase of 259.09%, and a net profit of 1.2032 million yuan, up 109.07% year-on-year [1]